HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
24 mai 2022 08h00 HE
|
HiberCell, Inc.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced...
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
28 avr. 2022 08h00 HE
|
HiberCell, Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutic candidates to address therapeutic resistance, cancer relapse and metastasis,...
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
03 mars 2022 08h00 HE
|
HiberCell, Inc.
In-person presentation taking place Wednesday, March 9, in the session beginning at 5:00pm MSTPresentation in Trained Immunity in Disease Treatment Session at Keystone Symposia in Banff, AB,...
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
24 févr. 2022 08h00 HE
|
HiberCell, Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, has initiated...
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer
14 déc. 2021 08h00 HE
|
HiberCell
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
07 déc. 2021 10h58 HE
|
HiberCell
Open-label phase 2 clinical trial is actively recruiting new patients and opening new sitesResults to be presented in a poster session at SABCS 2021 on December 8, 2021NEW YORK, Dec. 07, 2021 (GLOBE...
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer
30 sept. 2021 08h00 HE
|
HiberCell
Expands Board of Directors with Appointment of Cindy Jacobs, PhD, MD NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat...
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
08 sept. 2021 08h00 HE
|
HiberCell
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today that the U.S. Food and...
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
16 août 2021 08h00 HE
|
HiberCell
NEW YORK and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today the...
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
29 juin 2021 08h00 HE
|
HiberCell
NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....